RA Capital Management L.P. Has $1.45 Billion Stake in Ascendis Pharma A/S (NASDAQ:ASND)

RA Capital Management L.P. reduced its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 3.9% in the third quarter, Holdings Channel.com reports. The institutional investor owned 9,710,428 shares of the biotechnology company’s stock after selling 397,972 shares during the period. Ascendis Pharma A/S makes up about 16.7% of RA Capital Management L.P.’s holdings, making the stock its largest holding. RA Capital Management L.P. owned 0.16% of Ascendis Pharma A/S worth $1,449,864,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Westfield Capital Management Co. LP grew its stake in Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after buying an additional 170,942 shares during the last quarter. Avoro Capital Advisors LLC grew its stake in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after buying an additional 229,995 shares during the last quarter. Janus Henderson Group PLC grew its stake in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after buying an additional 267,881 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after purchasing an additional 155,971 shares in the last quarter. Finally, Fred Alger Management LLC grew its stake in shares of Ascendis Pharma A/S by 65.0% in the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock worth $41,879,000 after purchasing an additional 120,952 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ASND shares. Jefferies Financial Group increased their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. The Goldman Sachs Group increased their price target on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Stifel Nicolaus increased their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. TD Cowen decreased their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Finally, Wedbush restated an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Stock Down 0.3 %

Shares of NASDAQ ASND opened at $131.01 on Thursday. Ascendis Pharma A/S has a 12 month low of $101.43 and a 12 month high of $161.00. The company has a market cap of $7.94 billion, a price-to-earnings ratio of -16.26 and a beta of 0.67. The business has a fifty day simple moving average of $131.37 and a 200-day simple moving average of $132.53.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.